ACP3 Targeted -PET/ CT in Prostate Cancer
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult patients (aged 18 years or older);
• Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
• Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans;
• Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Locations
Other Locations
China
The First Affliated Hospital of Guilin Medical University
RECRUITING
Guilin
Contact Information
Primary
Xingyu Mu, PhD
muxingyu1992@hotmail.com
86 13347631119
Backup
Wei Fu
fuwei19700513@163.com
86 13977385850
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 100
Treatments
Experimental: ACP3 PET/CT
Each subject receives a single intravenous injection of radiolabeld ACP3 and undergoes PET/CT imaging within the specified time.
Related Therapeutic Areas
Sponsors
Leads: Guilin Medical University, China